Health

AstraZeneca’s COVID-19 vaccine trial data

On March 23, Reuters was more than a minute ahead with news that leading U.S. health agency Data Safety Monitoring Board has concerns that AstraZeneca may have included outdated information on its latest COVID-19 vaccine trial.

Market Impact

The news sent AstraZeneca shares down 2% in premarket trading.



Article Tags
Topics of Interest: Health
Type: Reuters News First
Sectors: Pharmaceuticals & Healthcare
Regions: North America
Win Types: Speed
Media Types: Text
Customer Impact: Major Global Story
Sign up for email updates

Subscribe
Sign up for email updates